performed to assess evolution of HRU and medical costs over time. Similar analysis was conducted for Medicare-eligible patients. The total HRU and costs for the follow-up period were $5,961 and $6,004, respectively. This was compared with a base case analysis for which HRU and costs were $5,486 and $5,524, respectively. The results indicated that the intervention is cost-effective over a 5-year period for Medicare-eligible patients.

**Conclusions:** The findings from this study suggest that the intervention is a cost-effective strategy for managing chronic obstructive pulmonary disease in Medicare-eligible patients. Further research is needed to evaluate the long-term impact of this intervention on health outcomes and costs.